Rights issue along with positive study results, page-4

First 4 Last

Share
Profile

Follow
stotes

3,516 Posts.

299

25/09/17

11:32

Post #: 27434664
Share

Originally posted by Newrotothis ↑

One possible reason for trading halt rather than just releasing the results which have already been presented to a public forum... to use the huge share price reaction as an opportunity to raise badly needed capital.

The collapse of the Italian deal leave NTI without necessary revenues to get us through to FDA approval without having to cutback on research or marketing. European expansion has been slower than expected. However if these results are as positive as Carrick presenting them would suggest, then this is perfect opportunity to launch a fund raise for another $5m. There would be huge demand as at last we finally have proof that the technology works, and is on track for FDA.

$5m is currently 1/3rd of the market cap, but is also the expected income they have lost from the Italians. This would leave the company looking in a very healthy state post positive news + healthy balance sheet!

Without the capital raise I would expect the stock to double on Wednesday to 33p, therefore it would be roughly a 1 for 6 rights, and stock would trade around 28p post rights. I'll take that thanks.

Just a thought and purely speculation on their options.

Expand

The collapse of the Italian deal leave NTI without necessary revenues to get us through to FDA approval without having to cutback on research or marketing.

Expand

Why do you believe the Italian deal "collapsed"?

The Italian distribution update clearly states it's renegotiated its terms.

NTI Price at posting: 16.5¢ Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

NIS

Aurum Resources bumps Boundiali gold project tenement stake to 80%

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

There are more pages in this discussion • 27 more messages in this thread...

First 4 Last

Add NTI (ASX) to my watchlist

(20min delay)
Last 7.0¢		Change 0.000(0.00%)		Mkt cap ! $64.55M

Open	High	Low	Value	Volume
7.1¢	7.1¢	6.9¢	$16.74K	240.7K

Buyers (Bids)

No.	Vol.	Price($)
1	16000	6.9¢

Sellers (Offers)

Price($)	Vol.	No.
7.0¢	253628	2

View Market Depth

No.	Vol.	Price($)
4	589299	0.070
1	36231	0.069
5	240000	0.068
2	255000	0.067
3	262000	0.066

Price($)	Vol.	No.
0.072	100000	1
0.074	40000	1
0.075	738582	2
0.076	90000	1
0.077	190000	3

Last trade - 10.43am 29/11/2024 (20 minute delay)

NTI (ASX) Chart

Rights issue along with positive study results, page-4

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Aurum Resources bumps Boundiali gold project tenement stake to 80%

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Buyers (Bids)

Sellers (Offers)